-
Innovation Ranking
NewInnovation Ranking – Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc (Paratek) is a e biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. The company focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. Nuzyra (Omadacycline), the company’s lead product candidate is an USFDA-approved broad-spectrum antibiotic for the treatment of adults with community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections caused by susceptible bacteria. Its other product Seysara...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Omadacycline Tosylate in Mycobacterium Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Omadacycline Tosylate in Mycobacterium Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Omadacycline Tosylate in Mycobacterium Infections Drug Details: Omadacycline tosylate (Nuzyra) is...
-
Product Insights
Cystitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cystitis - Drugs In Development, 2023’, provides an overview of the Cystitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cystitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Osteomyelitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteomyelitis - Drugs In Development, 2023’, provides an overview of the Osteomyelitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Anthrax – Drugs In Development, 2023
Global Markets Direct’s, ‘Anthrax - Drugs In Development, 2023’, provides an overview of the Anthrax pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Drugs In Development, 2023
Global Markets Direct’s, ‘Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Drugs In Development, 2023’, provides an overview of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Community Acquired Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community Acquired Pneumonia - Drugs In Development, 2023’, provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorinostat in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vorinostat in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vorinostat in Marginal Zone B-cell Lymphoma Drug Details: Vorinostat...